Code
lsting <- as_listing(
out,
key_cols = c("TRT01A", "CRTNPT", "AGSXRC", "AVISIT"),
disp_cols = names(out),
main_title = "Listing of Vital Signs: Safety-Evaluable Patients",
main_footer = "Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range."
)
head(lsting, 20)
Listing of Vital Signs: Safety-Evaluable Patients
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Diastolic Blood
Pressure, Systolic Blood
Weight Sitting Diastolic Blood Pressure, Systolic Blood Respiratory Rate
Result Temperature Result Result Pressure, Sitting Pressure, Pulse Rate Result Result
Study (Kg); Weight (C); Temperature Rate (Pa); Sitting (Pa); Sitting (beats/min); Pulse Rate (breaths/min); Respiratory Rate
Treatment Center/Subject ID Age/Sex/Race Visit Day Range:(40-100) Change from BL Range:(36.1-37.2) Change from BL Range:(80-120) Change from BL Range:(120-180) Change from BL Range:(60-100) Change from BL Range:(12-20) Change from BL
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
A: Drug X BRA-1/105 38/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 189 90.96 24.62 36.79 -1.88 101.10 -12.65 181.05/H 3.70 84.91 -2.05 18.34 1.13
WEEK 2 DAY 15 323 41.40 -24.93 36.52 -2.14 111.02 -2.72 132.47 -44.88 71.54 -15.42 9.81/L -7.40
WEEK 3 DAY 22 492 60.55 -5.78 35.03/L -3.64 88.35 -25.39 112.67/L -64.68 33.75/L -53.22 21.23/H 4.02
WEEK 4 DAY 29 550 69.69 3.36 35.71/L -2.95 100.74 -13.00 194.88/H 17.53 97.51 10.54 12.50 -4.71
WEEK 5 DAY 36 628 81.64 15.30 36.01/L -2.65 123.17/H 9.43 140.33 -37.02 62.50 -24.47 10.91/L -6.30
BRA-1/134 47/M/WHITE WEEK 1 DAY 8 203 42.95 -12.51 36.39 -1.38 112.71 26.38 148.69 -52.75 69.12 3.72 15.31 -2.84
WEEK 2 DAY 15 326 20.36/L -35.09 35.75/L -2.03 98.42 12.09 188.08/H -13.36 68.79 3.40 17.60 -0.55
WEEK 3 DAY 22 363 46.33 -9.12 35.43/L -2.34 97.88 11.55 160.05 -41.39 90.21 24.81 18.15 0.00
WEEK 4 DAY 29 367 43.83 -11.62 36.01/L -1.76 98.97 12.65 132.19 -69.25 88.39 23.00 19.62 1.48
WEEK 5 DAY 36 417 31.75/L -23.71 36.35 -1.42 124.26/H 37.94 134.30 -67.14 88.64 23.25 20.08/H 1.94
BRA-1/42 36/M/BLACK OR AFRICAN AMERICAN WEEK 1 DAY 8 265 115.27/H 8.42 37.35/H -1.67 107.32 5.90 173.89 27.40 66.14 26.13 9.23/L 7.13
WEEK 2 DAY 15 313 45.84 -61.01 36.01/L -3.01 110.97 9.55 144.75 -1.74 109.71/H 69.70 7.18/L 5.08
WEEK 3 DAY 22 325 85.70 -21.14 37.71/H -1.31 124.13/H 22.71 89.08/L -57.41 90.29 50.28 25.16/H 23.05
WEEK 4 DAY 29 535 44.64 -62.21 36.44 -2.58 79.51/L -21.91 140.78 -5.71 82.44 42.43 14.06 11.95
WEEK 5 DAY 36 729 85.21 -21.64 35.78/L -3.23 105.26 3.84 126.60 -19.89 88.71 48.70 25.98/H 23.87
BRA-1/93 34/F/ASIAN WEEK 1 DAY 8 402 47.51 -35.34 35.50/L -0.83 94.27 17.98 98.82/L -61.71 72.44 -7.85 14.97 0.22
WEEK 2 DAY 15 460 67.64 -15.21 37.96/H 1.62 109.98 33.69 104.21/L -56.32 104.70/H 24.41 14.90 0.16
WEEK 3 DAY 22 464 53.06 -29.78 36.33 -0.01 90.17 13.87 139.66 -20.87 111.13/H 30.85 22.86/H 8.12
WEEK 4 DAY 29 496 61.68 -21.17 33.52/L -2.82 112.76 36.47 128.82 -31.70 72.89 -7.39 20.77/H 6.03
WEEK 5 DAY 36 538 53.98 -28.86 35.71/L -0.63 80.20 3.91 137.16 -23.37 96.63 16.35 18.10 3.36
——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Baseline is the patient's last observation prior to initiation of study drug. Abnormalities are flagged as high (H) or low (L) if outside the Roche standard reference range.